File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: MAPK1 p.D321N mutation confers sensitive to erlotinib in head and neck squamous cell carcinoma (HNSCC)

TitleMAPK1 p.D321N mutation confers sensitive to erlotinib in head and neck squamous cell carcinoma (HNSCC)
Authors
Issue Date1-Aug-2020
PublisherAmerican Association for Cancer Research
Citation
Cancer Research, 2020, v. 80, n. 16 How to Cite?
Abstract

The annual incidence of head and neck squamous cell carcinoma (HNSCC) is ~0.88 million worldwide (IARC, WHO 2018). Despite great success of precision medicine in major cancers such as lung cancer and breast cancers, there are limited precision therapies for HNSCC. We previously reported an HNSCC patient whose tumor harbored a somatic MAPK1 p.E322K mutation demonstrating exceptional clinical response to erlotinib, an EGFR inhibitor. Subsequent laboratory investigation confirmed the ability of MAPK1 p.E322K to hyperactivate EGFR, thus causing erlotinib sensitivity in HNSCC models, both in vitro and in vivo. Here, we sequenced 105 tumors from Hong Kong (HK) HNSCC patients by next-generation sequencing (NGS) on MAPK1 gene and we found a 5.71% rate (6/105 tumors) of MAPK1 somatic mutation in HK-HNSCC. This rate appears to be relatively higher than the 1.75% (9/521 tumors) rate in the US-TCGA HNSCC cohort (P=0.0288). Apart from the MAPK1 p.E322K mutation found in the US-TCGA HNSCC cohort, we identified novel MAPK1 p.R135K and p.D321N mutations in our HK cohort which were absent in the US TCGA HNSCC. Pan-cancer mapping of MAPK1 somatic mutations revealed that MAPK1 p.R135K and p.D321N mutations are also recurrent hotspot mutation in TCGA pan-cancers (32 cancer types). Strikingly, based on the X-ray crystallography of the human MAPK1 protein, R135 and D321 amino acid residues both reside on the same kinase interaction motif (KIM) domain as E322 (all are within a 13Å distance in 3D). Thus, we further investigated if MAPK1 p.R135K and p.D321N mutations might function similarly as MAPK1 p.E322K mutant in terms of their abilities to drive HNSCC growth, and erlotinib sensitivity in HNSCC models. We employed the same FaDu retroviral infection method to study these mutations as we did previously, and we found that MAPK1 p.D321N (P<0.0001) was a driver for HNSCC proliferation, while MAPK1 p.R135K was not (all vs. MAPK1-wildtype). Subsequent in vivo erlotinib treatment experiments with xenografts bearing these mutants and MAPK1-wildtype showed that MAPK1 p.D321N tumors demonstrated heightened sensitivity to erlotinib with marked reduction of tumor size, tumor cell positivity, as well as membranous pEGFR expression when compared to vehicle treatment (P=0.0037). Whereas MAPK1 p.R135K tumors only showed a trend for erlotinib sensitivity (P=0.0646), with reduction in membranous p-EGFR expression by erlotinib in the tumors. Thus, MAPK1 p.D321N mutation confers erlotinib-sensitivity in HNSCC system. Further clinical investigation is warranted to further explore the relationship between various MAPK1 mutations and erlotinib sensitivity in HNSCC patients.


Persistent Identifierhttp://hdl.handle.net/10722/337594
ISSN
2023 Impact Factor: 12.5
2023 SCImago Journal Rankings: 3.468
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorNgan, HL-
dc.contributor.authorPoon, PHY-
dc.contributor.authorSu, YX-
dc.contributor.authorChan, JYK-
dc.contributor.authorLo, KW-
dc.contributor.authorYeung, CK-
dc.contributor.authorLiu, YC-
dc.contributor.authorWong, E-
dc.contributor.authorLi, H-
dc.contributor.authorLau, CW-
dc.contributor.authorPiao, WY-
dc.contributor.authorLui, VWY -
dc.date.accessioned2024-03-11T10:22:20Z-
dc.date.available2024-03-11T10:22:20Z-
dc.date.issued2020-08-01-
dc.identifier.citationCancer Research, 2020, v. 80, n. 16-
dc.identifier.issn0008-5472-
dc.identifier.urihttp://hdl.handle.net/10722/337594-
dc.description.abstract<p>The annual incidence of head and neck squamous cell carcinoma (HNSCC) is ~0.88 million worldwide (IARC, WHO 2018). Despite great success of precision medicine in major cancers such as lung cancer and breast cancers, there are limited precision therapies for HNSCC. We previously reported an HNSCC patient whose tumor harbored a somatic <em>MAPK1</em> p.E322K mutation demonstrating exceptional clinical response to erlotinib, an EGFR inhibitor. Subsequent laboratory investigation confirmed the ability of <em>MAPK1</em> p.E322K to hyperactivate EGFR, thus causing erlotinib sensitivity in HNSCC models, both <em>in vitro</em> and <em>in vivo</em>. Here, we sequenced 105 tumors from Hong Kong (HK) HNSCC patients by next-generation sequencing (NGS) on <em>MAPK1</em> gene and we found a 5.71% rate (6/105 tumors) of <em>MAPK1</em> somatic mutation in HK-HNSCC. This rate appears to be relatively higher than the 1.75% (9/521 tumors) rate in the US-TCGA HNSCC cohort (P=0.0288). Apart from the <em>MAPK1</em> p.E322K mutation found in the US-TCGA HNSCC cohort, we identified novel <em>MAPK1</em> p.R135K and p.D321N mutations in our HK cohort which were absent in the US TCGA HNSCC. Pan-cancer mapping of MAPK1 somatic mutations revealed that <em>MAPK1</em> p.R135K and p.D321N mutations are also recurrent hotspot mutation in TCGA pan-cancers (32 cancer types). Strikingly, based on the X-ray crystallography of the human MAPK1 protein, R135 and D321 amino acid residues both reside on the same kinase interaction motif (KIM) domain as E322 (all are within a 13Å distance in 3D). Thus, we further investigated if <em>MAPK1</em> p.R135K and p.D321N mutations might function similarly as <em>MAPK1</em> p.E322K mutant in terms of their abilities to drive HNSCC growth, and erlotinib sensitivity in HNSCC models. We employed the same FaDu retroviral infection method to study these mutations as we did previously, and we found that <em>MAPK1</em> p.D321N (P<0.0001) was a driver for HNSCC proliferation, while <em>MAPK1</em> p.R135K was not (all vs. <em>MAPK1</em>-wildtype). Subsequent <em>in vivo</em> erlotinib treatment experiments with xenografts bearing these mutants and <em>MAPK1</em>-wildtype showed that <em>MAPK1</em> p.D321N tumors demonstrated heightened sensitivity to erlotinib with marked reduction of tumor size, tumor cell positivity, as well as membranous pEGFR expression when compared to vehicle treatment (P=0.0037). Whereas <em>MAPK1</em> p.R135K tumors only showed a trend for erlotinib sensitivity (P=0.0646), with reduction in membranous p-EGFR expression by erlotinib in the tumors. Thus, <em>MAPK1</em> p.D321N mutation confers erlotinib-sensitivity in HNSCC system. Further clinical investigation is warranted to further explore the relationship between various <em>MAPK1</em> mutations and erlotinib sensitivity in HNSCC patients.<br></p>-
dc.languageeng-
dc.publisherAmerican Association for Cancer Research-
dc.relation.ispartofCancer Research-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titleMAPK1 p.D321N mutation confers sensitive to erlotinib in head and neck squamous cell carcinoma (HNSCC)-
dc.typeArticle-
dc.identifier.doi10.1158/1538-7445.AM2020-1792-
dc.identifier.volume80-
dc.identifier.issue16-
dc.identifier.eissn1538-7445-
dc.identifier.isiWOS:000590059304083-
dc.publisher.placePHILADELPHIA-
dc.identifier.issnl0008-5472-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats